PURE Bioscience (OTCMKTS:PURE – Get Free Report) was the recipient of a large decline in short interest in October. As of October 30th, there was short interest totaling 1,982 shares, a decline of 54.8% from the October 15th total of 4,381 shares. Based on an average daily volume of 26,909 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the company’s stock are short sold.
PURE Bioscience Price Performance
Shares of PURE Bioscience stock remained flat at $0.07 during midday trading on Friday. The company had a trading volume of 9,187 shares, compared to its average volume of 21,797. The firm has a market cap of $9.10 million, a PE ratio of -3.50 and a beta of 0.34. The firm has a 50-day moving average price of $0.07 and a 200 day moving average price of $0.07. PURE Bioscience has a 52 week low of $0.04 and a 52 week high of $0.10.
PURE Bioscience Company Profile
PURE Bioscience develops and commercializes antimicrobial products based on silver dihydrogen citrate (SDC), a proprietary formulation designed to control bacteria and other microorganisms. The company focuses on applications where surface hygiene and food safety are important. Its offerings include SDC-based disinfectant and sanitizer products for hard surfaces, including products intended for food-processing and food-service environments. PURE Bioscience also pursues commercial partnerships to market its technology and products.
Featured Stories
- Five stocks we like better than PURE Bioscience
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
